



## Intellia Therapeutics to Participate at June Healthcare Investor Conferences

May 30, 2019

CAMBRIDGE, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both *in vivo* and *ex vivo*, will participate in the following upcoming healthcare conferences in June:

### **Tuesday, June 4, 2019**

#### **Jefferies Healthcare Conference**

Location: New York, NY

### **Tuesday, June 18, 2019**

#### **Raymond James Life Sciences and MedTech Conference**

Location: New York, NY

Time: 1:15 p.m. ET

A live webcast of Intellia's presentation at the Raymond James Conference will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at [www.intelliatx.com](http://www.intelliatx.com). To access the webcast, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia's website for approximately 14 days following the conference.

### **About Intellia Therapeutics**

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients' diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at [intelliatx.com](http://intelliatx.com) and follow us on Twitter @intelliatweets.

### **Investor Contact:**

Lina Li

Senior Manager, Investor Relations

+1 857-706-1612

[lina.li@intelliatx.com](mailto:lina.li@intelliatx.com)

### **Media Contact:**

Jennifer Mound Smoter

Senior Vice President, External Affairs & Communications

+1 857-706-1071

[jenn.smoter@intelliatx.com](mailto:jenn.smoter@intelliatx.com)



Source: Intellia Therapeutics, Inc.